Role of vitamin D and its receptor in regulation of mechanisms of immune inflammation in patients with ischemic heart disease

Coronary heart disease still underlies high morbidity and mortality in people of working age. Thus, today one of the most important tasks facing clinical cardiology is the search for new molecular genetic predictors of coronary artery disease associated with the unfavorable course of this disease and the development of complications. In the present review, we analyzed the available data on the mechanisms of vitamin D interrelation with the development of immune inflammation in patients with coronary heart disease. The role of vitamin D and its receptor in cardiovascular diseases and in the development of coronary heart disease, in particular, is considered.
Recent studies showed that vitamin D deficiency is a new risk factor for the development of atherosclerosis and immune inflammation. Immune damage of the vascular wall increases the risk of acute coronary syndrome, especially in patients with a predisposition to atherothrombosis. Vitamin D has a multilevel effect on immune inflammation mechanisms by restoring the balance in the system of pro- and anti-inflammatory cytokines. The protective effects of vitamin D on immune inflammation in the vascular wall are realized through vitamin D receptors. The present work re-viewed the studies describing possible mechanisms of immune inflammation regulation by vitamin D and its receptor and activation of immune inflammation in patients with vitamin D deficiency. Further studies of mechanisms of influence of vitamin D receptor on the suppression of immune inflammation are needed.

1. Ragino YuI, Kuzminykh NA, Shcherbakova LV, et al. Prevalence of coronary heart disease and its association with lipid and non-lipid risk factors in a population aged 25–45 years in Novosibirsk. Russian Journal of Cardiology 2019; 24 (6):78–84. In Russian

2. Dogan MV, Grumbach IM, Michaelson JJ, et al. Integrated genetic and epigenetic prediction of coronary heart disease in the Framingham Heart Study. PLoS One Res 2018; 13(1):e0190549. DOI: 10.1371/journal.pone.0190549.

3. Grygiel-Gorniak B. Peroxisome proliferatoractivated receptors and their ligands: nutritional and clinical implications — a review. G. Nutr. J. 2014; 13:17. DOI: 10.1186/1475-2891-13-17.

4. Li A, Zhang W, Zhang H, et al. Vitamin D/vitamin D receptor, autophagy and inflammation relevant diseases. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2017; 42(8):979–985. DOI: 10.11817/j.issn.1672-7347.2017.08.017.

5. Jamali N, Sorenson СМ, Sheibani N. Vitamin D and regulation of vascular cell function. Am J Physiol Heart Circ Physiol 2018; 314(4):H753–H765. DOI: 10.1152/ajpheart.00319.2017.

6. Sassi F, Tamone C, D’Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients 2018; 10(11):1656. DOI: 10.3390/nu10111656.

7. Kosmatova OV, Myagkova MA, Skripnikova IA. The effects of vitamin D and calcium on the cardiovascular system: safety issues. Preventive medicine. 2020; 23(3): 140–148. In Russian

8. Feinleib M, Kannel WB, Garrison RJ, et al. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975; 4(4):518–525. DOI: 10.1016/0091-7435(75)90037-7.

9. Dudinskaya EN, Tkacheva ON. The role of vitamin D in the development of arterial hypertension. Cardiovascular therapy and prevention. 2012; 11(3):77–81.

10. Fiscella K, Franks P. Vitamin D, race, and cardiovascular mortality. Ann fam med 2010; 8(1):11–8. DOI: 10.1370/afm.1035.

11. Zipes DP. Warning: the short days of winter may be hazardous to your health. Circulation. 1999; 100(15):1590–1592. DOI: 10.1161/01.cir.100.15.1590.

12. Ginde AA, Scragg R, Schwartz RS, et al. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009; 57(9):1595–1603. DOI: 10.1111/j.1532-5415.2009.02359.x.

13. Ng LL, Sandhu JK, Squire IB, et al. Vitamin D andprognosis in acute myocardial infarction. Int J Cardiol. 2013; 168(3):2341–2346. DOI: 10.1016/j.ijcard.2013.01.030.

14. Bonakdaran S, Varasteh AR. Correlation between serum 25 hydroxy vitamin D3 and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients. Saudi Med J. 2009; 30(4):509–514.

15. Kim DH, Meza CA, Clarke H, et al. Vitamin D and Endothelial Function. Nutrients. 2020; 12(2):575. DOI: 10.3390/nu12020575.

16. Syal SK, Kapoor A, Bhatia E, et al. Vitamin D deficiency, coronary artery disease, and Endothelial Dysfunction: Observations from a coronary angiographic study in Indian patients. J Invasive Cardiol. 2012; 24(8): 385–389.

17. Lin L, Zhang L, Li C, et al. Vitamin D and Vitamin D Receptor: New Insights in the Treatment of Hypertension. Curr Protein Pept Sci. 2019; 20(10):984–995. DOI: 10.2174/1389203720666190807130504.

18. Tay HM, Yeap WH, Dalan R, et al. Increased monocyte-platelet aggregates and monocyt-endothelial adhesion in healthy individuals with vitamin D deficiency. Faser J. 2020; 34(8):11133–11142. DOI: 10.1096/fj.202000822R.

19. Mandarino NR, Júnior Fd, Salgado JV, et al. Is Vitamin D Deficiency a New Risk Factor for Cardiovascular Disease? Open Cardiovasc Med J. 2015; 9:40–49. DOI: 10.2174/1874192401509010040.

20. Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA. 1988; 85(10): 3294–3298. DOI: 10.1073/pnas.85.10.3294.

21. Dorsch MP, Nemerovski CW, Ellingrod VL, et al. Vitamin D receptor genetics on extracellular matrix biomarkers and hemodynamics in systolic heart failure. J Cardiovasc Pharmacol Ther. 2014; 19(5):439–445. DOI: 10.1177/1074248413517747

22. Lu S, Guo S, Hu F, et al. The Associations Between the Polymorphisms of Vitamin D Receptor and Coronary Artery Disease. A Systematic Review and Meta-Analysis. Medicine. 2016; 95(21):e3467. DOI:10.1097/MD.0000000000003467.

23. Fang Y, van Meurs JB, d’Alesio A, et al. Promoter and 3’-untranslated-region haplotypes in the Vitamin D Receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am J Hum Genet. 2005; 77(5):807–823. DOI: 10.1086/497438.

24. He L, Wang M. Association of vitamin d receptor-a gene polymorphisms with coronary heart disease in Han Chinese. Int J Clin Exp Med. 2015; 8(4):6224–6229.

25. Abu el Maaty MA, Hassanein SI, Sleem HM, et al. Vitamin D receptor gene poly-morphisms (TaqI and ApaI) in relation to 25-hydroxyvitamin D levels and coronary artery disease incidence. J Recept Signal Transduct Res. 2015; 35:391–395. DOI: 10.3109/10799893.2014.959593.

26. Mathieu C. Vitamin D and the immune system: Getting it right. IBMS BoneKEy. 2011; 8:178–186. DOI: 10.1138/20110505.

27. Zdrenghea MT, Makrinioti H, Bagacean C, et al. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol. 2017; 27(1). DOI: 10.1002/rmv.1909.

28. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun. 2017; 85:78–97. DOI: 10.1016/j.jaut.2017.07.007.

29. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 2010; 17(1):R19–R38. DOI: 10.1677/ERC-09-0139.

30. Equils O, Naiki Y, Shapiro AM, et al. 1,25-Dihydroxyvitamin D inhibits lipopoly-saccharideinduced immune activation in human endothelial cells. Clin Exp Immunol. 2006; 143(1):58–64. DOI: 10.1111/j.1365-2249.2005.02961.x.

31. Talmor Y, Bernheim J, Klein O, et al. Calcitriol blunts proatherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest. 2008; 38(8):548–554. DOI: 10.1111/j.1365-2362.2008.01977.x.

32. Laird E, McNulty H, Ward M, et al. Vitamin D deficiency is associated with in-flammation in older Irish adult. J Clin Endocrinol Metab. 2014; 99(5):1807–1815. DOI: 10.1210/jc.2013-3507.

33. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Harb Perspect Biol. 2009; 1(6):a001651. DOI: 10.1101/cshperspect.a001651.

34. Lorente-Cebrián S, Eriksson A, Dunlop T, et al. Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur. J. Nutr. 2012; 51:335–342. DOI: 10.1007/s00394-011-0218-z.

35. Hii CS, Ferrante A. The Non-Genomic Actions of Vitamin D. Nutrients. 2016; 8(3):135. DOI: 10.3390/nu8030135.

36. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. of Biol. Chem. 2009; 284(10):6038–6042. DOI: 10.1074/jbc.C800207200.

37. Jablonski KL, Chonchol M, Pierce GL, et al. 25- Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011; 57(1):63–69. DOI: 10.1161/HYPERTENSIONAHA.110.160929.

38. Liang K, Dong SR, Peng H. Serum levels and clinical significance of IFN-γ and IL-10 in patients with coronary heart disease. Eur Rev Med Pharmacol Sci. 2016; 20(7):1339-1343.

39. Merke J, Milde P, Lewicka S, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25- dihydroxyvitamin D3. J Clin Invest. 1989; 83(6):1903–1915. DOI: 10.1172/JCI114097.

40. Stach K, Kalsch AI, Nguyen XD, et al. 1α,25-Dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology. 2011; 118(2):107–115. DOI: 10.1159/000327547.

41. McMullan CJ, Borgi L, Curhan GC, et al. The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial. J Hypertens. 2017; 35(4):822–829. DOI: 10.1097/HJH.0000000000001220.

42. Szeto FL, Reardon CA, Yoon D, et al. Vitamin D receptor signaling inhibits ather-osclerosis in mice. Mol Endocrinol. 2012; 26(7):1091–1101. DOI: 10.1210/me.2011-1329.

43. Ostapenko VA, Grishechkina IA, Viktorova IA. Receptors that activate peroxi-some proliferation and ischemic heart disease. Omsk Scientific Bulletin. 2012; 2: 14–17. In Russian [Остапенко В.А., Гришечкина И.А., Викторова И.А. Рецепторы, активирующие пролиферацию пероксисом, и ишемическая болезнь сердца. Омский научный вестник. 2012; 2:14–17].

44. Huang FC, Huang SC. Differential Effects of Statins on Inflammatory Interleukin-8 and Antimicrobial Peptide Human Β-Defensin 2 Responses in Salmonella- Infected Intestinal Epithelial Cells. Int J Mol Sci. 2018;19(6):1650. DOI: 10.3390/ijms19061650.

45. Sahebkar A, Reiner Z, Simental-Mendia LE, et al. Impact of Statin Therapy on Plasma Vitamin D Levels: A Systematic Review and Meta-Analysis. Curr Pharm Des. 2017; 23(6):861–869. DOI: 10.2174/1381612822666161006150542.

46. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins. Cardiovasc Drugs Ther. 2009; 23(4):295–299. DOI: 10.1007/s10557-009-6181-8.

47. Ertugrul DT, Yavuz B, Ci H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin. Cardiovasc Ther. 2011; 29(2):146–152. DOI: 10.1111/j.1755-5922.2010.00141.x.